BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 33325154)

  • 1. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation Status of
    Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
    Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
    Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
    Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
    Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
    Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
    BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Summers MG; Smith CG; Maughan TS; Kaplan R; Escott-Price V; Cheadle JP
    Clin Cancer Res; 2017 Jun; 23(11):2742-2749. PubMed ID: 27815357
    [No Abstract]   [Full Text] [Related]  

  • 14. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded Low Allele Frequency
    Loree JM; Dowers A; Tu D; Jonker DJ; Edelstein DL; Quinn H; Holtrup F; Price T; Zalcberg JR; Moore MJ; Karapetis CS; O'Callaghan CJ; Waring P; Kennecke HF; Hamilton SR; Kopetz S
    Clin Cancer Res; 2021 Jan; 27(1):52-59. PubMed ID: 33087330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
    Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
    Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
    Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D
    Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.